Outcomes’10 receives the Certificate of Innovative Company at the national level

18 Nov 2021

Today our team has received the Innovative Company Certificate awarded by the Association of Science and Technology Parks of Spain. It is a certification that uses blockchain technology and that aims to give visibility to national innovation.

“Innovation is one of the fundamental pillars of our company, this new certification supports it and allows us to connect with companies like us that offer innovative solutions and adapt to changes in the healthcare environment” says Susana Aceituno, associate director of Outcomes’10.

Through this certification, issued by the Association of Science and Technology Parks of Spain (APTE), it is intended to generate a public access registry in which all innovative companies at the national level will appear.

“This certificate, which will be available to be consulted by organizations and entities from different national and international fields, will be registered through public access to the APTE blockchain network,” they explain from Espaitec in a statement.

The objective of this initiative is to use blockchain technology for the certification of Spanish companies and entities characterized by innovation. “In this way, it is intended to create the largest registry of innovative Spanish companies and entities to give them the greatest possible visibility, as well as provide them with the added value of facilitating a certification as an innovative entity and the ability to demonstrate it to any body that requests it” they add.

Upon obtaining this certification, we receive an official seal that we have already published on our website, so that any user can consult the information related to the APTE Outcomes’10 innovation certificate.

Outcomes'10 receives the Certificate of Innovative Company at the national level

También puede interesarte…

17 de March de 2025

GRACE project: Transforming cardiovascular care through innovation and collaboration

Castellón, May 17th 2025 – Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, accounting for 17.9 million fatalities each year—a number expected to rise to 22 million by 2030, according to the WHO. Encompassing a range of conditions...
11 de September de 2024

Press release: Productlife Group acquires Outcomes´10

Productlife Group acquires Outcomes´10, expanding European market access capabilities
11 de March de 2024

Spiomet4Health Project

Outcomes'10 participates in the SPIOMET4HEALTH clinical trial to evaluate a world-first treatment for PCOS.
Skip to content
Privacy Summary

This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.